Mesoblast (ASX:MSB) Shares Look Stretched As Its 355% Three Year Run

Simply Wall St · 2d ago

Mesoblast has delivered a very large 3 year share price gain, yet the stock is currently trading well below its highs after a year of weaker returns, which puts fresh focus on whether the current market value lines up with the sales the business is generating today. With new management moves and product updates reshaping expectations, the open question is how much revenue the market is implicitly pricing into the Mesoblast story right now.

  • After rising roughly 3.6x over the past 3 years, Mesoblast now carries a track record that can strongly influence how investors weigh its share price against its actual sales base.
  • Recent steps to prepare rexlemestrocel-L and Ryoncil for broader commercial use may support expectations for stronger future sales and a different balance between current revenue and the price investors are willing to pay for that stream.
  • The analysts covering Mesoblast have run their own numbers. See what analysts think Mesoblast's shares could be worth.

The issue now is whether Mesoblast's current share price is justified by its sales when set against the Fair Ratio benchmark.

This same question about how much sales are already priced in can also be tested across other healthcare names using the 7 healthcare AI stocks.

Is Mesoblast Getting Expensive on Sales?

P/S is a useful lens for Mesoblast because the business is still loss making and investors are mainly paying for current and potential sales. On this measure, Mesoblast trades on a P/S ratio of about 12.4x, which is above the Biotechs industry average of roughly 11.7x and also ahead of the peer group near 10.0x. That points to the market assigning the stock a premium valuation relative to many similar healthcare stocks on raw revenue.

The Fair Ratio, which blends factors such as growth expectations, margins, size and risk, sits below the current P/S level so the shares screen as overvalued on this framework. Because recent management hires and commercial preparation for rexlemestrocel L and Ryoncil have sharpened the story around future products, investors appear willing to pay more per dollar of sales than these benchmarks imply. For anyone considering Mesoblast, the key question is whether the existing and expected revenue base justifies that premium or leaves limited room for disappointment. Explore the numbers behind Mesoblast's P/S valuation.

ASX:MSB P/S Ratio as at Nov 2026
ASX:MSB P/S Ratio as at Nov 2026

The Mesoblast Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Mesoblast's valuation puzzle leaves off by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth materially more or materially less than today, based on scenarios set out on the Community page. Rather than relying on a single multiple or model output, each narrative lays out the key building blocks behind its fair value view so you can compare those assumptions with Mesoblast's actual results over time.

One of the top narratives on Mesoblast: 52% undervalued

This Narrative is the analyst consensus Narrative on Simply Wall St. It compiles analysts' consensus price target and revenue and earnings forecasts, rather than reflecting one person's view.

"The chronic low back pain Phase III program for rexlemestrocel L targets millions of patients and a setting where opioid use is common, aligning the product with an ongoing healthcare shift toward non opioid therapies…"

Discover why this Narrative puts Mesoblast at 52% undervalued.

The next Mesoblast question is what expectations are already mapped out a few years ahead

Valuation frames where Mesoblast trades today, but a different lens asks how far profit and revenue projections extend over the next few years and how that picture lines up with the current share price. Explore where analysts expect Mesoblast to be in a few years.